Top Markets
#1 Pleasing Gold Pleasing Gold +1,498.13%
#2 PulseChain PulseChain +58.12%
#3 Merlin's Seal BTC Merlin's Seal BTC +33.53%
#4 BOOK OF MEME BOOK OF MEME +29.96%
#5 Ontology Gas Ontology Gas +28.98%
#6 Neiro Neiro +24.50%
#7 ConstitutionDAO ConstitutionDAO +24.22%
#8 Unit Pump Unit Pump +20.90%
#9 Pump.fun Pump.fun +20.90%
#10 DogBull DogBull +19.72%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPO
Rank in Stocks #26438
Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in... Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.
Share Price
$2.20
Last synced: 2021-08-26
Market Cap
$40.53M
Change (1 day)
-0.90%
Change (1 year)
0.00%
Country
US
Trade Aerpio Pharmaceuticals, Inc. (ARPO)

Category

Healthcare
P/E ratio for Aerpio Pharmaceuticals, Inc. (ARPO)
P/E ratio as of 2026 TTM: 0
According to Aerpio Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Aerpio Pharmaceuticals, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.